Dashboard
Manage Tickers

NUVL Nuvalent, Inc.

Nasdaq nuvalent.com


$ 108.90 $ 1.77 (1.65 %)    

Thursday, 20-Nov-2025 10:17:52 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 611.84 $ 0.17 (0.03 %)
DIA $ 467.85 $ 1.17 (0.25 %)
SPY $ 673.94 $ 1.01 (0.15 %)
TLT $ 89.11 $ 0.13 (0.14 %)
GLD $ 376.27 $ 1.14 (0.3 %)
$ 107.13
$ 107.31
$ 108.23 x 3
$ 108.81 x 102
$ 106.82 - $ 109.18
$ 55.54 - $ 112.53
2,169,460
na
7.79B
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nuvalent-new-drug-application-for-zidesamtinib-ros1-selective-inhibitor-reeives-fdas-approval-to-treat-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer
Nuvalent New Drug Application For Zidesamt...
11/19/2025 21:22:33

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

reported-earlier-nuvalent-prices-underwritten-offering-of-4950496-class-a-shares-at-101-each-to-raise-500m
Reported Earlier, Nuvalent Prices Underwri...
11/19/2025 07:00:09

goldman-sachs-maintains-buy-on-nuvalent-raises-price-target-to-135
Goldman Sachs Maintains Buy on Nuvalent, R...
11/18/2025 17:51:02

Goldman Sachs analyst Richard Law maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $120 to $135.

baird-maintains-outperform-on-nuvalent-raises-price-target-to-158
Baird Maintains Outperform on Nuvalent, Ra...
11/18/2025 15:40:01

Baird analyst Colleen Kusy maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $112 to $158.

guggenheim-maintains-buy-on-nuvalent-raises-price-target-to-155
Guggenheim Maintains Buy on Nuvalent, Rais...
11/18/2025 14:56:39

Guggenheim analyst Brad Canino maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $125 to $155.

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/17/2025 21:07:48

nuvalent-announces-500m-class-a-common-stock-offering
Nuvalent Announces $500M Class A Common St...
11/17/2025 21:02:17

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

nuvalent-reports-31-response-rate-in-patients-with-advanced-form-of-lung-cancer
Nuvalent Reports 31% Response Rate In Pati...
11/17/2025 18:03:10

Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1...

stifel-maintains-buy-on-nuvalent-raises-price-target-to-135
Stifel Maintains Buy on Nuvalent, Raises P...
11/17/2025 17:47:03

Stifel analyst Laura Prendergast maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $115 to $135.

jazz-pharmaceuticals-sigma-lithium-zymeworks-and-other-big-stocks-moving-higher-on-monday
Jazz Pharmaceuticals, Sigma Lithium, Zymew...
11/17/2025 16:39:23

hc-wainwright--co-maintains-buy-on-nuvalent-raises-price-target-to-155
HC Wainwright & Co. Maintains Buy on Nuval...
11/17/2025 16:28:06

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price targ...

nuvalent-shared-topline-data-from-alkove-1-phase-12-trial-for-neladalkibin-pre-treated-patients-with-advanced-alk-positive-non-small-cell-lung-cancer-additionally-the-company-shared-the-first-report-of-preliminary-data-from-phase-2-exploratory-cohort
Nuvalent Shared Topline Data From ALKOVE-1...
11/17/2025 11:34:20

In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64%...

nuvalent-to-present-topline-alkove-1-trial-data-for-neladalkib-on-november-17-2025-at-800am-et
Nuvalent To Present Topline ALKOVE-1 Trial...
11/14/2025 21:04:23

Company to host webcast and conference call on November 17, 2025 at 8:00am ETCAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nu...

this-waste-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Waste Management Analyst Begins Cover...
11/12/2025 13:52:09

canaccord-genuity-initiates-coverage-on-nuvalent-with-buy-rating-announces-price-target-of-126
Canaccord Genuity Initiates Coverage On Nu...
11/12/2025 12:06:49

Canaccord Genuity analyst John Newman initiates coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Tar...

nuvalent-to-present-patient-reported-outcomes-data-from-the-phase-2-portion-of-the-arros-1-phase-12-clinical-trial-of-zidesamtinib-and-encore-pivotal-efficacy-and-safety-data-from-the-arros-1-trial-at-2025-iaslc-asco-north-america-conference-on-lung-cancer
Nuvalent To Present Patient-Reported Outco...
11/04/2025 22:17:01

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for c...

ubs-maintains-buy-on-nuvalent-raises-price-target-to-132
UBS Maintains Buy on Nuvalent, Raises Pric...
10/31/2025 15:56:30

UBS analyst David Dai maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $114 to $132.

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

nuvalent-q3-eps-170-misses-136-estimate
Nuvalent Q3 EPS $(1.70) Misses $(1.36) Est...
10/30/2025 10:38:46

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.36) by...

piper-sandler-maintains-overweight-on-nuvalent-raises-price-target-to-128
Piper Sandler Maintains Overweight on Nuva...
10/27/2025 13:13:20

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $11...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION